SECURE-CODE-WARRIOR
23.7.2024 14:01:30 CEST | Business Wire | Press release
Secure Code Warrior, the global, developer-driven security leader, today announced the availability of SCW Trust Agent – an industry-first solution that assesses the specific security competencies of developers for every code commit. This innovative offering enables CISOs and application security (AppSec) teams to embrace a Secure-by-Design approach with deeper visibility into their organizations’ software development security posture.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240723230392/en/
SCW Trust Agent provides visibility and control to scale developer driven security (Photo: Business Wire)
The launch of SCW Trust Agent follows the company’s rollout of SCW Trust Score, the first industry benchmark that quantifies the security posture of organizations’ developer teams. Both innovations apply over 20 million learning data points collected from 250,000 developers around the world. These deliver quantitative mechanisms that, when paired with Secure Code Warrior’s agile learning platform, become an integral part of an organization’s secure software development lifecycle.
“At Secure Code Warrior, we are unlocking new value for CISOs by giving them an easy-to-deploy solution to measure the health of code commits and visibility into the hundreds of source code repositories in their organization,” said Pieter Danhieux, Co-founder and CEO, Secure Code Warrior. “Our innovations are putting organizations in a better position to bridge the visibility gap between a developer's skill sets and quality of code produced without sacrificing development velocity.”
SCW Trust Agent works seamlessly with any Git-based code repository including GitHub, GitLab, Atlassian Bitbucket and more. With every commit, it looks to see if the developer making it has the prescribed secure code skillset in the commit’s programming language. It uses this information to give a rating on the health of that commit and aggregates these ratings across all of your repositories.
SCW Trust Agent delivers greater control and flexibility for developer gatekeeping. It allows administrators to set up policies and criteria, ensuring developers meet a baseline set of standards and expectations before developing code. For any gaps in developer skills, they can reference the SCW agile learning platform to upskill their language specific knowledge and competencies.
Overall SCW Trust Agent delivers:
- Improved Security Controls: Customize policy configuration based on the sensitivity of project requirements
- Comprehensive Visibility: Actionable insights into the security posture of every commit across all of your code repositories
- Developer-Led Security at Scale: Deliver projects securely at speed - allowing application security teams to focus on the most sensitive security reviews
For more information on SCW Trust Agent, visit: www.scwtrustagent.com
About Secure Code Warrior
Secure Code Warrior is a secure coding platform that sets the standards that keep our digital world safe. We do this by providing the world’s leading agile learning platform that delivers the most effective secure coding solution for developers to learn, apply, and retain software security principles. More than 600 enterprises trust Secure Code Warrior to implement agile learning security programs and ensure the applications they release are free of vulnerabilities.
For more information about Secure Code Warrior, visit www.securecodewarrior.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240723230392/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom